Novartis AG (NYSE:NVS) – Equities research analysts at Leerink Swann boosted their FY2020 earnings per share estimates for shares of Novartis AG in a report released on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will earn $5.80 per share for the year, up from their previous estimate of $5.79. Leerink Swann has a “Market Perform” rating and a $91.00 price objective on the stock.

Several other research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research note on Tuesday, September 19th. BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Cowen and Company set a $90.00 price target on shares of Novartis AG and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company. Novartis AG currently has a consensus rating of “Hold” and an average price target of $85.28.

COPYRIGHT VIOLATION WARNING: “Leerink Swann Comments on Novartis AG’s FY2020 Earnings (NVS)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/24/leerink-swann-comments-on-novartis-ags-fy2020-earnings-nvs.html.

Shares of Novartis AG (NYSE NVS) traded down 3.044% on Tuesday, hitting $83.295. 6,433,843 shares of the stock were exchanged. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The company has a 50-day moving average price of $85.66 and a 200 day moving average price of $82.41. The company has a market cap of $195.15 billion, a PE ratio of 30.411 and a beta of 0.73.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. The firm had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The business’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $1.23 earnings per share.

A number of hedge funds have recently made changes to their positions in the stock. Farr Miller & Washington LLC DC grew its position in Novartis AG by 0.3% during the 2nd quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock valued at $247,000 after purchasing an additional 10 shares during the last quarter. FCG Advisors LLC grew its position in Novartis AG by 0.3% during the 2nd quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock valued at $357,000 after purchasing an additional 12 shares during the last quarter. Washington Trust Bank grew its position in Novartis AG by 0.3% during the 2nd quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after purchasing an additional 14 shares during the last quarter. North Star Investment Management Corp. grew its position in Novartis AG by 1.0% during the 2nd quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after purchasing an additional 16 shares during the last quarter. Finally, Ledyard National Bank grew its position in Novartis AG by 0.9% during the 2nd quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after purchasing an additional 30 shares during the last quarter. 10.94% of the stock is currently owned by institutional investors.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.